Cogent Biosciences (COGT) Other Non-Current Liabilities (2020 - 2026)

Cogent Biosciences' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $62000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 1140.0% year-over-year to $62000.0; the TTM figure through Mar 2026 stood at $62000.0 (up 1140.0% YoY), while the FY2025 annual figure was $33000.0, changed N/A from the prior year.
• Other Non-Current Liabilities was $62000.0 for Q1 2026 at Cogent Biosciences, up from $33000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $2.4 million in Q3 2025 to a low of $5000.0 in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $1.1 million across 3 years, with a median of $881000.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities plunged 44.44% in 2022, then surged 1140.0% in 2026.
• A 3-year view of Other Non-Current Liabilities shows it stood at $1.7 million in 2022, then slumped by 98.06% to $33000.0 in 2025, then surged by 87.88% to $62000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $62000.0 (Q1 2026), $33000.0 (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.